Development and characterization of α-Mangostin-loaded polymeric nanoparticles for intranasal brain delivery: pharmacokinetic evaluation and preliminary in-vitro neuroprotective assessment
α-Mangostin (αM) belongs to a bioactive xanthone derivative, having antioxidant and potential neuroprotective properties. However, its therapeutic applications are restricted due to limited aqueous solubility and limited penetration across the blood-brain barrier (BBB) of the brain. The present study aimed to develop αM-loaded polymeric nanoparticles for a intranasal delivery and improved brain availability. αM was initially selected through a multiscale in-silico studies. The optimized αM-PNPs (polylactide-co-glycolide as PLGA nanoparticles) were characterized using the physicochemical, in-vitro , and ex - vivo evaluations, followed by long-term stability studies. I n vivo pharmacokinetics were conducted in rats and a preliminary neuroprotective activity was evaluated in OGD/R-induced BV-2 cells. The in-silico analysis showed a favorable docking score (-9.980 kcal/mol) for αM and formed a stable complex with the PPAR-γ receptor throughout a 200ns MD simulation, supporting its predicted interaction with PPAR-γ. The optimized αM-PNPs exhibited a mean particle size of 232.63 ± 5.03 nm, a zeta potential of -20.9 ± 2.27 mV, an encapsulation efficiency (%EE) of 84.7 ± 3.57%, a drug loading (%DL) of 14.5 ± 1.08%, and a polydispersity index (PDI) of 0.191 ± 0.024. The αM-PNPs exhibited a biphasic drug release profile, with approximately 88% cumulative drug release over 12 h. However, based on the reported regression coefficients, the release profile was best fitted to first-order and Hixson-Crowell models (r² = 0.9976). The steady state permeation flux value ( J ss ) of αM-PNPs (573.98 ± 17.1 µg/h.cm 2 ) was relatively higher than αM-SUS (316.8 ± 10.6 µg/h.cm 2 ), demonstrating an intense modulation of the BBB for improved penetration into the brain. The optimized αM-PNPs demonstrated a satisfactory long-term stability under the controlled storage conditions. αM-PNPs showed enhanced brain drug availability and improved in vitro cytoprotective activity (BV-2) as compared to αM-SUS. Overall, the developed intranasal αM-PNPs represent a promising non-invasive strategy for enhancing nose-to-brain delivery of αM.
Authors
- Tahir Khuroo (ORCID: https://orcid.org/0000-0002-9327-5737)
- Zahid Rafiq (ORCID: https://orcid.org/0000-0001-7281-0780)
- Yogeeta O. Agrawal (ORCID: https://orcid.org/0000-0002-3293-5607)
- Aarti V. Belgamwar (ORCID: https://orcid.org/0000-0002-6298-5488)
- Afzal Hussain (ORCID: https://orcid.org/0000-0002-6275-5375)
- Mohammad A. Altamimi (ORCID: https://orcid.org/0000-0003-4877-864X)
- Mohd Usman Mohd Siddique (ORCID: https://orcid.org/0000-0001-9503-1771)
- Azim Ansari (ORCID: https://orcid.org/0000-0003-1757-9437)
- Chaitali Pardeshi
- Prafull Shinde
- Mrugendra Potdar
Institutions
- Texas A&M Health Science Center (US)
- The University of Texas at El Paso (US)
- Narsee Monjee Institute of Management Studies (IN)
- King Saud University (SA)
- Shri Vile Parle Kelavani Mandal (IN)
- Texas A&M University (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1038/s41598-026-80036-9
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00